ProCE Banner Activity

Optimizing Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Clinical Thought

In this commentary, an expert faculty member discusses best practices for identifying and treating advanced cutaneous squamous cell carcinoma (cSCC), including strategies for integrating immune checkpoint inhibitors into treatment plans and management of immune-related adverse events.

Released: August 22, 2022

Expiration: August 21, 2023

No longer available for credit.



Nikhil I. Khushalani

Nikhil I. Khushalani, MD

Senior Member and Vice Chair
Department of Cutaneous Oncology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida


This program is supported by educational grants from Merck Sharp & Dohme Corp; Regeneron Pharmaceuticals, Inc. and Sanofi; and Taiho Oncology, Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and RNs


Nikhil I. Khushalani, MD: consultant/advisor: Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar, Novartis, Pfizer, Regeneron; research support (paid to institution): Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Huya Bioscience International, Merck, Novartis, Regeneron, Replimune; individual publicly traded stocks and stock options: Amarin, Asensus Surgical, Bellicum Pharmaceuticals; other: Bristol-Myers Squibb, Celgene, Nektar, Regeneron, Replimune.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.



Additional Information

Program Medium

This program has been made available online.